BIOTECHNOLOGY VALUE FUND L P 13D and 13G filings for Celldex Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2021-02-11 4:33 pm Sale | 2020-12-31 | 13G | Celldex Therapeutics, Inc. CLDX | BIOTECHNOLOGY VALUE FUND L P | 0 0.000% | -2,740,000 (Position Closed) | Filing |
| 2020-06-26 5:28 pm Purchase | 2020-06-16 | 13G | Celldex Therapeutics, Inc. CLDX | BIOTECHNOLOGY VALUE FUND L P | 2,740,000 7.200% | 2,740,000 (New Position) | Filing |